Novo Nordisk (NVO) Stock Forecast & Price Target

Compare

9,907 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NVO Analyst Ratings

Moderate Buy

4 Buy

3 Hold

1 Sell

Based on 8 analysts giving stock ratings to

Novo

Nordisk

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NVO Stock 12 Month Forecast

Average Price Target

$94.63

▲(35.73%Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Novo Nordisk in the last 3 months. The average price target is $94.63 with a high forecast of $141.39 and a low forecast of $61.00. The average price target represents a 35.73% change from the last price of $69.72.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"60":"$60","81":"$81","102":"$102","123":"$123","144":"$144"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":141.39398,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$141.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":94.63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$94.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$61.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[60,81,102,123,144],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72.83,78.1041523076923,83.37830461538462,88.65245692307693,93.92660923076923,99.20076153846153,104.47491384615384,109.74906615384616,115.02321846153846,120.29737076923077,125.57152307692309,130.8456753846154,136.1198276923077,{"y":141.39398,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72.83,74.50692307692307,76.18384615384615,77.86076923076922,79.53769230769231,81.21461538461539,82.89153846153846,84.56846153846153,86.24538461538461,87.92230769230768,89.59923076923076,91.27615384615385,92.95307692307692,{"y":94.63,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72.83,71.92,71.01,70.1,69.19,68.28,67.37,66.46,65.55,64.64,63.73,62.82,61.91,{"y":61,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":133.39,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.39,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.61,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.58,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.67,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.67,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.44,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.04,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.49,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.62,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.03,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.6,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.83,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$141.39

Average Price Target$94.63

Lowest Price Target$61.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$82

Buy

17.61%

Upside

Reiterated

06/24/25

Novo Nordisk's strong financial performance and solid earnings call results are the most significant factors supporting its stock score. Despite technical challenges and a reduced outlook, the company’s strategic initiatives and robust valuation position it well for future growth.

Evan SeigermanBMO Capital

BMO Capital

$64

Hold

-8.20%

Downside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Solid Biosciences (NASDAQ: SLDB) and Novo Nordisk (NYSE: NVO)

Jasper HellwegArgus Research

Argus Research

$110→$90

Buy

29.09%

Upside

Reiterated

06/18/25

Novo Nordisk (NVO) Gets a Buy from Argus Research

Michael NedelcovychTD Cowen

TD Cowen

$105

Buy

50.60%

Upside

Reiterated

06/18/25

Analysts Offer Insights on Healthcare Companies: Zai Lab (NASDAQ: ZLAB), LifeMD (NASDAQ: LFMD) and Novo Nordisk (NYSE: NVO)

Rajesh KumarHSBC

HSBC

$160→$102

Buy

46.30%

Upside

Reiterated

04/28/25

Novo Nordisk price target lowered to $102 from $160 at HSBCNovo Nordisk price target lowered to $102 from $160 at HSBC

Seamus FernandezGuggenheim

Guggenheim

―

Hold

―

Downgraded

04/17/25

Novo Nordisk downgraded to Neutral from Buy at GuggenheimNovo Nordisk downgraded to Neutral from Buy at Guggenheim

Peter VerdultExane BNP Paribas

Exane BNP Paribas

$61

Sell

-12.51%

Downside

Initiated

04/15/25

Novo Nordisk initiated with an Underperform at BNP Paribas ExaneNovo Nordisk initiated with an Underperform at BNP Paribas Exane

Sachin JainBank of America Securities

Bank of America Securities

$141.39

Buy

102.80%

Upside

Reiterated

03/28/25

Confident Buy Rating for Novo Nordisk Amid Sales Guidance Adjustments and Market Challenges

Thibault BoutherinMorgan Stanley

Morgan Stanley

$99

Hold

42.00%

Upside

Reiterated

03/27/25

Hold Rating for Novo Nordisk Amid Competitive Pressures and Market Uncertainties

Unknown AnalystBerenberg Bank

Not Ranked

Berenberg Bank

$100→$90

Hold

29.09%

Upside

Reiterated

03/24/25

Unknown AnalystStifel Nicolaus

Not Ranked

Stifel Nicolaus

―

Hold

―

Downgraded

03/03/25

Wan NurhayatiCFRA

CFRA

$122→$90

Hold

29.09%

Upside

Reiterated

01/21/25

Novo Nordisk (NVO) PT Lowered to $90 at CFRACFRA analyst Wan Nurhayati lowered the price target on Novo Nordisk (NYSE: NVO) to $90.00 (from $122.00) while maintaining a Hold rating.

James QuigleyGoldman Sachs

Goldman Sachs

$148→$124

Buy

77.85%

Upside

Reiterated

01/13/25

Novo Nordisk (NVO) PT Lowered to $124 at Goldman SachsGoldman Sachs analyst James Quigley lowered the price target on Novo Nordisk (NYSE: NVO) to $124.00 (from $148.00) while maintaining a Buy rating.

Unknown AnalystBernstein

Not Ranked

Bernstein

―

Hold

―

Upgraded

01/06/25

Bernstein SocGen Group upgrades Novo Nordisk (NVO) to Market PerformBernstein SocGen Group upgraded Novo Nordisk (NYSE: NVO) from Underperform to Market Perform.

Peter WelfordJefferies

Jefferies

$81.5

Sell

16.90%

Upside

Reiterated

12/20/24

Jefferies sees Novo dropping 'at least' 10%-15% on obesity data Jefferies sees Novo dropping 'at least' 10%-15% on obesity data

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$82

Buy

17.61%

Upside

Reiterated

06/24/25

Evan SeigermanBMO Capital

BMO Capital

$64

Hold

-8.20%

Downside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Solid Biosciences (NASDAQ: SLDB) and Novo Nordisk (NYSE: NVO)

Jasper HellwegArgus Research

Argus Research

$110→$90

Buy

29.09%

Upside

Reiterated

06/18/25

Novo Nordisk (NVO) Gets a Buy from Argus Research

Michael NedelcovychTD Cowen

TD Cowen

$105

Buy

50.60%

Upside

Reiterated

06/18/25

Analysts Offer Insights on Healthcare Companies: Zai Lab (NASDAQ: ZLAB), LifeMD (NASDAQ: LFMD) and Novo Nordisk (NYSE: NVO)

Rajesh KumarHSBC

HSBC

$160→$102

Buy

46.30%

Upside

Reiterated

04/28/25

Novo Nordisk price target lowered to $102 from $160 at HSBCNovo Nordisk price target lowered to $102 from $160 at HSBC

Seamus FernandezGuggenheim

Guggenheim

―

Hold

―

Downgraded

04/17/25

Novo Nordisk downgraded to Neutral from Buy at GuggenheimNovo Nordisk downgraded to Neutral from Buy at Guggenheim

Peter VerdultExane BNP Paribas

Exane BNP Paribas

$61

Sell

-12.51%

Downside

Initiated

04/15/25

Novo Nordisk initiated with an Underperform at BNP Paribas ExaneNovo Nordisk initiated with an Underperform at BNP Paribas Exane

Sachin JainBank of America Securities

Bank of America Securities

$141.39

Buy

102.80%

Upside

Reiterated

03/28/25

Confident Buy Rating for Novo Nordisk Amid Sales Guidance Adjustments and Market Challenges

Thibault BoutherinMorgan Stanley

Morgan Stanley

$99

Hold

42.00%

Upside

Reiterated

03/27/25

Hold Rating for Novo Nordisk Amid Competitive Pressures and Market Uncertainties

Unknown AnalystBerenberg Bank

Not Ranked

Berenberg Bank

$100→$90

Hold

29.09%

Upside

Reiterated

03/24/25

Unknown AnalystStifel Nicolaus

Not Ranked

Stifel Nicolaus

―

Hold

―

Downgraded

03/03/25

Wan NurhayatiCFRA

CFRA

$122→$90

Hold

29.09%

Upside

Reiterated

01/21/25

Novo Nordisk (NVO) PT Lowered to $90 at CFRACFRA analyst Wan Nurhayati lowered the price target on Novo Nordisk (NYSE: NVO) to $90.00 (from $122.00) while maintaining a Hold rating.

James QuigleyGoldman Sachs

Goldman Sachs

$148→$124

Buy

77.85%

Upside

Reiterated

01/13/25

Unknown AnalystBernstein

Not Ranked

Bernstein

―

Hold

―

Upgraded

01/06/25

Bernstein SocGen Group upgrades Novo Nordisk (NVO) to Market PerformBernstein SocGen Group upgraded Novo Nordisk (NYSE: NVO) from Underperform to Market Perform.

Peter WelfordJefferies

Jefferies

$81.5

Sell

16.90%

Upside

Reiterated

12/20/24

Jefferies sees Novo dropping 'at least' 10%-15% on obesity data Jefferies sees Novo dropping 'at least' 10%-15% on obesity data

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novo Nordisk

1 Month

xxx

Success Rate

9/16 ratings generated profit

Average Return

+1.01%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 56.25% of your transactions generating a profit, with an average return of +1.01% per trade.

3 Months

xxx

Success Rate

13/24 ratings generated profit

Average Return

+0.66%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 54.17% of your transactions generating a profit, with an average return of +0.66% per trade.

1 Year

Sachin JainBank of America Securities

Success Rate

9/24 ratings generated profit

Average Return

-1.63%

reiterated a buy rating 3 months ago

Copying Sachin Jain's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -1.63% per trade.

2 Years

xxx

Success Rate

4/16 ratings generated profit

Average Return

-6.88%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of -6.88% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NVO Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NVO has received 6 Buy Ratings, 8 Hold Ratings, and 1 Sell Ratings. NVO average Analyst price target in the past 3 months is 94.63.

Each month's total comprises the sum of three months' worth of ratings.

NVO Financial Forecast

NVO Earnings Forecast

Next quarter’s earnings estimate for NVO is $0.91 with a range of $0.82 to $0.96. The previous quarter’s EPS was $0.99. NVO beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.11% of the time in the same period. In the last calendar year NVO has Preformed in-line its overall industry.

NVO Sales Forecast

Next quarter’s sales forecast for NVO is $11.73B with a range of $11.22B to $12.08B. The previous quarter’s sales results were $11.02B. NVO beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.48% of the time in the same period. In the last calendar year NVO has Preformed in-line its overall industry.

NVO Stock Forecast FAQ

What is NVO’s average 12-month price target, according to analysts?

Based on analyst ratings, Novo Nordisk’s 12-month average price target is 94.63.

What is NVO’s upside potential, based on the analysts’ average price target?

Novo Nordisk has 35.73% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NVO a Buy, Sell or Hold?

Novo Nordisk has a consensus rating of Moderate Buy which is based on 4 buy ratings, 3 hold ratings and 1 sell ratings.

What is Novo Nordisk’s price target?

The average price target for Novo Nordisk is 94.63. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $141.39 ,the lowest forecast is $61.00. The average price target represents 35.73% Increase from the current price of $69.72.

What do analysts say about Novo Nordisk?

Novo Nordisk’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of NVO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Novo Nordisk (NVO) Stock Forecast & Price Target

NVO Analyst Ratings

NVO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novo Nordisk

NVO Analyst Recommendation Trends

NVO Financial Forecast

NVO Earnings Forecast

NVO Sales Forecast

NVO Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts